Updates are available Correction dated 2026-06-17
Click to view Correction: https://doi.org/10.1186/s43058-026-01014-w
-
Authors
Mooney, Meagan
Weight, Charlene
Biondi, Mia J.
Grebely, Jason
Kronfli, Nadine
Barnett, Tamara
Bruneau, Julie
Dunn, Kate
Elakpa, Daniel N.
Etherington, Cole
Greenaway, Christina
Martel-Laferrière, Valérie
Mendlowitz, Andrew
Taylor, Natalie
Fontaine, Guillaume https://orcid.org/0000-0002-7806-814X
-
Funding
Funding for this research was provided by:
Institute of Health Services and Policy Research (PJT-517467)
- License Information
-
More Information
Article History
Received: 8 October 2025
Accepted: 1 December 2025
First Online: 18 December 2025
Change Date: 18 June 2026
Change Type: Update
Change Details: The article has been updated to correct the Competing Interests statement.
Change Date: 17 June 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s43058-026-01014-w
Declarations
:
: This study described above was reviewed and approved by the Research Ethics Board of McGill University, Faculty of Medicine and Health Sciences (protocol # 24-12-038). See Additional file 4 for REB approval.
: Not applicable; no data are contained in this study protocol paper.
: NK reports investigator-initiated studies from ViiV Healthcare, Abbvie, and Gilead, and honoraria from Abbvie, all outside this work. JB reports investigator-initiated studies from Gilead, and honoraria from Gilead and Abbvie, all outside this work. JG has received research grants, speaker fees, and participated on advisory boards for AbbVie, Abbott, bioLytical, Cepheid, Gilead Sciences, Hologic, and Roche. GF reports speaker fees/hospitality from Gilead and Abbvie, all outside this work and is an Associate Editor of Implementation Science Communications.
